BRAF mutation correlates with worse local–regional control following radiation therapy in patients with stage III melanoma

BACKGROUND: In patients with stage III melanoma, the use of adjuvant radiation therapy (RT) after lymph node dissection (LND) may be currently considered in selected high-risk patients to improve tumor control. Melanomas harbor BRAF mutations (BRAF+) in 40–50% of cases, the majority of which are on...

Descripción completa

Detalles Bibliográficos
Autores principales: Wolfe, Adam R., Chablani, Priyanka, Siedow, Michael R., Miller, Eric D., Walston, Steve, Kendra, Kari L., Wuthrick, Evan, Williams, Terence M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8449455/
https://www.ncbi.nlm.nih.gov/pubmed/34537078
http://dx.doi.org/10.1186/s13014-021-01903-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8449455/
https://www.ncbi.nlm.nih.gov/pubmed/34537078
http://dx.doi.org/10.1186/s13014-021-01903-5

Ejemplares similares